source
- Pfizer partners with China's Innovent Biologics on $10.5 billion deal for 12 early-stage cancer programsPfizer announced a collaboration with Innovent Biologics of China to develop a suite of cancer therapies. The agreement covers up to 12 early-stage antibody‑drug conjugates and multi‑specific anti…
- Merck touts promising ADC sacituzumab tirumotecan as potential cornerstone therapy at ASCOMerck highlighted a new antibody-drug conjugate, sacituzumab tirumotecan (sac-TMT), licensed from Chinese biotech Kelun-Biotech, at the ASCO meeting. The company said early clinical data have give…